{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:43:28Z","timestamp":1792226608774,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,13]]},"DOI":"10.7759\/cureus.13332","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T09:33:10Z","timestamp":1613295190000},"source":"Crossref","is-referenced-by-count":6,"title":["Review of Bone Modifying Agents in Metastatic Breast Cancer"],"prefix":"10.7759","author":[{"given":"Charumathi","family":"Raghu Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Talluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Mullangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manidhar R","family":"Lekkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Moftakhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman RE","year":"1987","unstructured":"Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987, 55:61-6. 10.1038\/bjc.1987.13","journal-title":"Br J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.04.008","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body JJ","year":"2017","unstructured":"Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, Amelio J. Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol. 2017, 115:67-80. 10.1016\/j.critrevonc.2017.04.008","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.02.004","article-title":"Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: a systematic review and network meta-analysis","volume":"137","author":"Tesfamariam Y","year":"2019","unstructured":"Tesfamariam Y, Jakob T, W\u00f6ckel A, et al.. Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: a systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2019, 137:1-8. 10.1016\/j.critrevonc.2019.02.004","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12609-018-0295-6","article-title":"Bone-modifying agents in early-stage and advanced breast cancer","volume":"10","author":"Heeke A","year":"2018","unstructured":"Heeke A, Nunes MR, Lynce F. Bone-modifying agents in early-stage and advanced breast cancer. Curr Breast Cancer Rep. 2018, 10:241-50. 10.1007\/s12609-018-0295-6","journal-title":"Curr Breast Cancer Rep"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol13050018","article-title":"Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?","volume":"13","author":"Gainford MC","year":"2006","unstructured":"Gainford MC, Dranitsaris G, Ooi W, Vanhuyse M, Clemons M. Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?. Curr Oncol. 2006, 13:187-90.","journal-title":"Curr Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00774","article-title":"Is de-escalated bisphosphonates therapy a suitable alternative to standard dosing in malignant tumor patients with bone metastases: a systematic review and meta-analysis","volume":"9","author":"Luo Q","year":"2019","unstructured":"Luo Q, Men P, Liu Z, Zhai S, Jiang M. Is de-escalated bisphosphonates therapy a suitable alternative to standard dosing in malignant tumor patients with bone metastases: a systematic review and meta-analysis. Front Oncol. 2019, 9:774. 10.3389\/fonc.2019.00774","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley DA","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012, 66:1139-46. 10.1111\/ijcp.12022","journal-title":"Int J Clin Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson AHG","year":"1993","unstructured":"Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993, 11:59-65. 10.1200\/JCO.1993.11.1.59","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial","volume":"14","author":"Conte PF","year":"1996","unstructured":"Conte PF, Latreille J, Mauriac L, et al.. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. J Clin Oncol. 1996, 14:2552-9. 10.1200\/JCO.1996.14.9.2552","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.491","article-title":"Palliative pamidronate treatment in patients with bone metastases from breast cancer","volume":"11","author":"Van Holten-Verzantvoort ATM","year":"1993","unstructured":"Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al.. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993, 11:491-8. 10.1200\/JCO.1993.11.3.491","journal-title":"J Clin Oncol"},{"key":"ref11","unstructured":"Food and Drug Administration. Xgeva (denosumab). (2020). Accessed: November 23, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0328","article-title":"Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis","volume":"20","author":"Wang Z","year":"2015","unstructured":"Wang Z, Qiao D, Lu Y, Curtis D, Wen X, Yao Y, Zhao H. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. Oncologist. 2015, 20:440-9. 10.1634\/theoncologist.2014-0328","journal-title":"Oncologist"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical oncology-cancer Care Ontario focused guideline update","volume":"35","author":"Van Poznak C","year":"2017","unstructured":"Van Poznak C, Somerfield MR, Barlow WE, et al.. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical oncology-cancer Care Ontario focused guideline update. J Clin Oncol. 2017, 35:3978-86. 10.1200\/JCO.2017.75.4614","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori D","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, et al.. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013, 14:663-70. 10.1016\/S1470-2045(13)70174-8","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein AL","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, et al.. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017, 317:48-58. 10.1001\/jama.2016.19425","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi GN","year":"2017","unstructured":"Hortobagyi GN, Van Poznak C, Harker WG, et al.. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol. 2017, 3:906-12. 10.1001\/jamaoncol.2016.6316","journal-title":"JAMA Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv284","article-title":"Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis","volume":"26","author":"Ibrahim MFK","year":"2015","unstructured":"Ibrahim MFK, Mazzarello S, Shorr R, et al.. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol. 2015, 26:2205-13. 10.1093\/annonc\/mdv284","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003474.pub4","article-title":"Bisphosphonates and other bone agents for breast cancer","author":"O\u2019Carrigan B","year":"2017","unstructured":"O\u2019Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017, CD003474. 10.1002\/14651858.CD003474.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2275","article-title":"Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis","volume":"19","author":"Palmieri C","year":"2013","unstructured":"Palmieri C, Fullarton JR, Brown J. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clin Cancer Res. 2013, 19:6863-72. 10.1158\/1078-0432.CCR-13-2275","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee P","year":"2014","unstructured":"Barrett-Lee P, Casbard A, Abraham J, et al.. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014, 15:114-22. 10.1016\/S1470-2045(13)70539-4","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701","article-title":"Long\u2010term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen LS","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, et al.. Long\u2010term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 2003, 98:1735-44. 10.1002\/cncr.11701","journal-title":"Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0828-1","article-title":"Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy","volume":"13","author":"De Cock E","year":"2005","unstructured":"De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer. 2005, 13:975-86. 10.1007\/s00520-005-0828-1","journal-title":"Support Care Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-008-0419-x","article-title":"Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease","volume":"134","author":"Mystakidou K","year":"2008","unstructured":"Mystakidou K, Stathopoulou E, Parpa E, Kouloulias V, Kouskouni E, Vlahos L. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. J Cancer Res Clin Oncol. 2008, 134:1303-10. 10.1007\/s00432-008-0419-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S103130","article-title":"Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority phase III trial","volume":"9","author":"von Au A","year":"2016","unstructured":"von Au A, Milloth E, Diel I, et al.. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority phase III trial. Onco Targets Ther. 2016, 9:4173-80. 10.2147\/OTT.S103130","journal-title":"Onco Targets Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi K","year":"2009","unstructured":"Fizazi K, Lipton A, Mariette X, et al.. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009, 27:1564-71. 10.1200\/JCO.2008.19.2146","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck AT","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, et al.. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010, 28:5132-9. 10.1200\/JCO.2010.29.7101","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5234","article-title":"Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy","volume":"14","author":"Lipton A","year":"2008","unstructured":"Lipton A, Steger GG, Figueroa J, et al.. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008, 14:6690-6. 10.1158\/1078-0432.CCR-07-5234","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2017.11.004","article-title":"Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries","volume":"11","author":"von Moos R","year":"2018","unstructured":"von Moos R, Body JJ, Rider A, et al.. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol. 2018, 11:1-9. 10.1016\/j.jbo.2017.11.004","journal-title":"J Bone Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5759","article-title":"How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?","volume":"29","author":"Gralow JR","year":"2011","unstructured":"Gralow JR, Lipton A, Stopeck AT. How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?. J Clin Oncol. 2011, 29:3591-2. 10.1200\/JCO.2011.36.5759","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1159\/000368844","article-title":"Side effects of bone-targeted therapies in advanced breast cancer","volume":"9","author":"Domschke C","year":"2014","unstructured":"Domschke C, Schuetz F. Side effects of bone-targeted therapies in advanced breast cancer. Breast Care. 2014, 9:332-6. 10.1159\/000368844","journal-title":"Breast Care"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body JJ","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH, et al.. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015, 51:1812-21. 10.1016\/j.ejca.2015.05.016","journal-title":"Eur J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12517","article-title":"Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures","volume":"13","author":"Pittman K","year":"2017","unstructured":"Pittman K, Antill YC, Goldrick A, Goh J, de Boer RH. Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac J Clin Oncol. 2017, 13:266-76. 10.1111\/ajco.12517","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref33","unstructured":"FDA. highlights of prescribing information. (2010). Accessed: December 10, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon T","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006, 17:897-907. 10.1093\/annonc\/mdj105","journal-title":"Ann Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson JR","year":"2005","unstructured":"Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005, 10:62. 10.1634\/theoncologist.10-1-52","journal-title":"Oncologist"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1177\/1049909114539035","article-title":"Palliative oncology: denosumab","volume":"32","author":"Prommer E","year":"2015","unstructured":"Prommer E. Palliative oncology: denosumab. Am J Hosp Palliat Med. 2015, 32:568-72. 10.1177\/1049909114539035","journal-title":"Am J Hosp Palliat Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.1982","article-title":"Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials","volume":"7","author":"Wang X","year":"2014","unstructured":"Wang X, Yang KH, Wanyan P, Tian JH. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials. Oncol Lett. 2014, 7:1997-2002. 10.3892\/ol.2014.1982","journal-title":"Oncol Lett"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.211","article-title":"Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents","volume":"10","author":"Campisi G","year":"2014","unstructured":"Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Futur Oncol. 2014, 10:257-75. 10.2217\/fon.13.211","journal-title":"Futur Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt KP","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004, 42:164-75. 10.1097\/01.mlr.0000108746.69256.45","journal-title":"Med Care"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1177\/0269216316639793","article-title":"Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project","volume":"31","author":"Porta-Sales J","year":"2017","unstructured":"Porta-Sales J, Garz\u00f3n-Rodr\u00edguez C, Llorens-Torrom\u00e9 S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017, 31:5-25. 10.1177\/0269216316639793","journal-title":"Palliat Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.1024","article-title":"Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial","volume":"28","author":"Stopeck A","year":"2010","unstructured":"Stopeck A, Fallowfield L, Patrick D, et al.. Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial. J Clin Oncol. 2010, 28:1024-1024. 10.1200\/jco.2010.28.15_suppl.1024","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-012-0414-8","article-title":"Treatment of bone metastases before the onset of pain","volume":"18","author":"Costa L","year":"2013","unstructured":"Costa L, Lipton A, Hadji P, Chen YM, Kosmidis P. Treatment of bone metastases before the onset of pain. Int J Clin Oncol. 2013, 18:531-8. 10.1007\/s10147-012-0414-8","journal-title":"Int J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-29","article-title":"Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark","volume":"11","author":"Jensen AT","year":"2011","unstructured":"Jensen AT, Jacobsen JB, N\u00f8rgaard M, Yong M, Fryzek JP, S\u00f8rensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer. 2011, 11:29. 10.1186\/1471-2407-11-29","journal-title":"BMC Cancer"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1200\/jop.2011.000212","article-title":"American Society of Clinical Oncology Clinical Practice Guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"7","author":"Van Poznak CH","year":"2011","unstructured":"Van Poznak CH, Temin S, Yee GC. American Society of Clinical Oncology Clinical Practice Guideline update on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract. 2011, 7:117-21. 10.1200\/jop.2011.000212","journal-title":"J Oncol Pract"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer: implications for management","volume":"36","author":"Plunkett TA","year":"2000","unstructured":"Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer. 2000, 36:476-82. 10.1016\/S0959-8049(99)00331-7","journal-title":"Eur J Cancer"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-89","article-title":"Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer","volume":"5","author":"Liauw W","year":"2005","unstructured":"Liauw W, Segelov E, Lih A, Dunleavy R, Links M, Ward R. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC Cancer. 2005, 5:89. 10.1186\/1471-2407-5-89","journal-title":"BMC Cancer"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1104-8","article-title":"Predicting skeletal complications in metastatic breast cancer raises challenges","volume":"123","author":"Van Poznak C","year":"2010","unstructured":"Van Poznak C. Predicting skeletal complications in metastatic breast cancer raises challenges. Breast Cancer Res Treat. 2010, 123:781-3. 10.1007\/s10549-010-1104-8","journal-title":"Breast Cancer Res Treat"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7278","article-title":"Exploiting machine learning for predicting skeletal-related events in cancer patients with bone metastases","volume":"7","author":"Wang Z","year":"2016","unstructured":"Wang Z, Wen X, Lu Y, Yao Y, Zhao H. Exploiting machine learning for predicting skeletal-related events in cancer patients with bone metastases. Oncotarget. 2016, 7:12612-22. 10.18632\/oncotarget.7278","journal-title":"Oncotarget"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7437","article-title":"Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance)","volume":"35","author":"Shapiro CL","year":"2017","unstructured":"Shapiro CL, Moriarty JP, Dusetzina S, et al.. Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin Oncol. 2017, 35:3949-55. 10.1200\/JCO.2017.73.7437","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/47063-review-of-bone-modifying-agents-in-metastatic-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:24:25Z","timestamp":1707506665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/47063-review-of-bone-modifying-agents-in-metastatic-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,13]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.13332","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,13]]}}}